Physician profile
Timothy E Sass
NPI 1265573166
$1,500.26
in general payments reported to CMS, 2019-2025
24 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $192 · 2021: $243 · 2022: $170 · 2023: $247 · 2024: $271 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $239.60 | 2019-2025 | Airsupra |
| Novo Nordisk INC | $179.27 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $158.88 | 2019-2023 | Jardiance, Mounjaro, Trulicity |
| Pfizer INC. | $147.42 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $112.80 | 2019-2025 | Capvaxive, Gardasil 9 |
| Exact Sciences Corporation | $104.26 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $101.64 | 2019-2023 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.88 | 2019-2023 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $63.29 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.46 | 2022 | |
| Sanofi Pasteur INC. | $40.70 | 2019-2020 | |
| Amarin Pharma, INC. | $39.40 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $25.60 | 2021-2022 | |
| Amgen INC. | $16.63 | 2024 | Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $16.38 | 2023 | Seglentis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bavarian Nordic A/S | $15.34 | 2025 | Vivotif |
| Alexion Pharmaceuticals, INC. | $15.00 | 2020 | |
| Seqirus USA INC | $14.69 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Eisai INC. | $14.50 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.81 | 2024 | Quviviq |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.66 | 2022 | |
| Vertical Pharmaceuticals, LLC | $13.44 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.07 | 2021 | |
| Sebela Pharmaceuticals INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Sass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.